Mouse Monoclonal FGFR1 Antibody

+ +

•  

   
     Western blot analysis of lysate from Hela cell line,  using FGFR1 Antibody (C-term)(Cat.  #P32875). P32875 was diluted at 1:2000.  A goat anti-mouse IgG H&L(HRP) at 1:3000 dilution was used as the secondary antibody. Lysate at 20μg.    

•  

   
     Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HeLa (human cervical epithelial adenocarcinoma cell line) cells labeling FGFR1 with P32875 at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-mouse IgG   secondary antibody at 1/200 dilution (green). Immunofluorescence image showing cytoplasm staining on HeLa cell line. The nuclear counter stain is DAPI (blue).    

•  

   
     P32875 staining FGFR1 in human brain tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,  paraffin-embedded sections).  Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).  Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

The fibroblast growth factor receptor 1 (FGFR1) is a transmembrane tyrosine kinase receptor that plays a critical role in regulating cell proliferation, differentiation, migration, and survival by binding to fibroblast growth factors (FGFs). Dysregulation of FGFR1 signaling, caused by gene amplification, mutations, or chromosomal translocations, is implicated in various cancers (e.g., breast, lung, and squamous cell carcinomas) and developmental disorders. FGFR1-targeted antibodies are therapeutic agents designed to inhibit aberrant FGFR1 activity. These antibodies typically block ligand binding, prevent receptor dimerization, or induce receptor internalization, thereby suppressing downstream signaling pathways like MAPK and PI3K/AKT.

Research on FGFR1 antibodies has gained momentum due to their potential to overcome resistance to other therapies, such as tyrosine kinase inhibitors (TKIs), and their specificity in targeting cancer cells with FGFR1 alterations. Preclinical studies demonstrate efficacy in reducing tumor growth and metastasis in models of FGFR1-driven cancers. However, challenges remain, including managing on-target toxicity in normal tissues expressing FGFR1 and addressing acquired resistance mechanisms. Clinical trials are ongoing to evaluate safety and efficacy in patients, often in combination with chemotherapy or immunotherapy. FGFR1 antibodies represent a promising precision oncology tool, though further optimization and biomarker-driven patient selection are needed to maximize therapeutic benefits.